Bimekizumab Treatment Is Associated with Improvements in Back Pain and Fatigue in Patients with Active Psoriatic Arthritis: 48-Week Results from a Phase 2b Study

被引：0
|
作者：
Deodhar, Atul [1 ]
Gossec, Laure [2 ,3 ]
Mease, Philip [4 ]
Coarse, Jason [5 ]
Edens, Heather [6 ]
De Peyrecave, Natasha [7 ]
Assudani, Deepak [7 ]
Ink, Barbara [7 ]
Ritchlin, Christopher [8 ]
机构：
[1] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[2] Sorbonne Univ, Paris, France
[3] Hop Univ Pitie Salpetriere, Paris, France
[4] Seattle Rheumatol Associates PLLC, Seattle, WA USA
[5] UCB Pharma, Raleigh, NC USA
[6] UCB Pharma, Smyrna, GA USA
[7] UCB Pharma, Slough, Berks, England
[8] Univ Rochester, Med Ctr, Dept Med, Rochester, NY 14642 USA
来源：
ARTHRITIS & RHEUMATOLOGY | 2020年 / 72卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0906
引用
收藏
页数：4
相关论文
共 50 条
  • [41] Efficacy and Safety of 108 Weeks of Bimekizumab Treatment in Patients with Psoriatic Arthritis: Interim Results from a Phase 2 Open-Label Extension Study
    McInnes, I. B.
    Merola, J. F.
    Mease, P. J.
    Coates, L. C.
    Schmitz, N.
    Joshi, P.
    Coarse, J.
    Ink, B.
    Ritchlin, C. T.
    SWISS MEDICAL WEEKLY, 2020, : 7S - 8S
  • [42] BIMEKIZUMAB IMPACT ON CORE GROUP FOR RESEARCH AND ASSESSMENT OF PSORIASIS AND PSORIATIC ARTHRITIS DOMAINS FOR PATIENTS WITH PSORIATIC ARTHRITIS: 52-WEEK RESULTS FROM FOUR PHASE 3 STUDIES
    Merola, Joseph F.
    Mease, Philip J.
    Deodhar, Atul
    Ink, Barbara
    Fleurinck, Carmen
    Bajracharya, Rajan
    Coarse, Jason
    Coates, Laura C.
    RHEUMATOLOGY, 2024, 63
  • [43] Bimekizumab impact on core group for research and assessment of psoriasis and psoriatic arthritis domains for patients with psoriatic arthritis: 52-week results from four phase 3 studies
    Merola, Joseph F.
    Mease, Philip J.
    Deodhar, Atul
    Ink, Barbara
    Fleurinck, Carmen
    Bajracharya, Rajan
    Coarse, Jason
    Coates, Laura C.
    RHEUMATOLOGY, 2024, 63
  • [44] Bimekizumab Maintained Efficacy Responses in Patients with Active Psoriatic Arthritis: Up to 2-Year Results from Two Phase 3 Studies
    Walsh, Jessica A.
    Merola, Joseph F.
    Ritchlin, Christopher T.
    Tanaka, Yoshiya
    Favalli, Ennio Giulio
    McGonagle, Dennis
    Thaci, Diamant
    Ink, Barbara
    Bajracharya, Rajan
    Coarse, Jason
    Tillett, William
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 1206 - 1209
  • [45] BIMEKIZUMAB DELIVERED SUSTAINED IMPROVEMENTS IN EFFICACY AND DEMONSTRATED A CONSISTENT SAFETY PROFILE IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: UP TO 2-YEAR RESULTS FROM TWO PHASE 3 STUDIES
    Mease, P. J.
    Merola, J. F.
    Landewe, R.
    McInnes, I. B.
    Ritchlin, C. T.
    Tanaka, Y.
    Asahina, A.
    Gossec, L.
    Ink, B.
    Heinrichs, A.
    Bajracharya, R.
    Shende, V
    Coarse, J.
    Coates, L. C.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2024, 42 (09) : 98 - 99
  • [46] EFFICACY AND SAFETY OF BIMEKIZUMAB IN ANKYLOSING SPONDYLITIS: 48-WEEK PATIENT-REPORTED OUTCOMES FROM A PHASE 2B, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY
    Van der Heijde, D.
    Gensler, L. S.
    Deodhar, A.
    Baraliakos, X.
    Poddubnyy, D.
    Kivitz, A.
    Farmer, M. K.
    Baeten, D.
    Goldammer, N.
    Coarse, J.
    Oortgiesen, M.
    Dougados, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 68 - 69
  • [47] SUSTAINED IMPROVEMENTS IN PRODUCTIVITY AT PAID WORK AND WITHIN HOUSEHOLD, AND INCREASED PARTICIPATION IN DAILY ACTIVITIES OVER TIME WITH CERTOLIZUMAB PEGOL IN PATIENTS WITH PSORIATIC ARTHRITIS: 48-WEEK RESULTS FROM THE RAPID-PSA STUDY
    Kavanaugh, A.
    Gladman, D.
    van der Heijde, D.
    Purcaru, O.
    Mease, P. J.
    VALUE IN HEALTH, 2013, 16 (07) : A570 - A570
  • [48] A phase II study of the combination of histamine dihydrochloride and interferon alpha-2b (IFN-α-2B) as initial therapy in chronic hepatitis C (HCV) patients:: 48-week results
    Lurie, Y
    Hyle, S
    Gehlsen, KR
    GASTROENTEROLOGY, 2001, 120 (05) : A381 - A382
  • [49] Bimekizumab in Patients with Psoriatic Arthritis: 3-Year Results for Overall and Tumor Necrosis Factor Inhibitor (TNFi)-Naive Populations from a Phase 2b Open-Label Extension Study
    Mease, Philip
    Deodhar, Atul
    Merola, Joseph
    McInnes, Iain
    Assudani, Deepak
    Bajracharya, Rajan
    Coarse, Jason
    Ink, Barbara
    Schett, Georg
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 2782 - 2785
  • [50] TREATMENT EFFECT OF USTEKINUMAB ON FATIGUE IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS FROM PSUMMIT 2
    Ritchlin, C.
    Rahman, P.
    Puig, L.
    Gottlieb, A. B.
    Kavanaugh, A.
    McInnes, I. B.
    Li, S.
    Wang, Y.
    Ganguly, R.
    Mendelsohn, A. M.
    Han, C.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2014, 32 (05) : 824 - 824
12345